Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 6
2015 1
2016 4
2017 3
2018 5
2019 7
2020 7
2021 15
2022 17
2023 21
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Human and Viral microRNA Expression in Acute and Chronic HIV Infections.
Lazzari E, Rozera G, Gagliardini R, Esvan R, Mondi A, Mazzotta V, Camici M, Girardi E, Antinori A, Maggi F, Abbate I. Lazzari E, et al. Among authors: gagliardini r. Viruses. 2024 Mar 23;16(4):496. doi: 10.3390/v16040496. Viruses. 2024. PMID: 38675839 Free PMC article.
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T cell counts in people living with HIV.
Vergori A, Cozzi-Lepri A, Tavelli A, Mazzotta V, Azzini AM, Gagliardini R, Mastrorosa I, Latini A, Pellicanò G, Taramasso L, Ceccherini-Silberstein F, Giannella M, Tacconelli E, Marchetti G, Monforte AD, Antinori A; Vax ICONA ORCHESTRA Study group. Vergori A, et al. Among authors: gagliardini r. Int J Infect Dis. 2024 Apr 19:107065. doi: 10.1016/j.ijid.2024.107065. Online ahead of print. Int J Infect Dis. 2024. PMID: 38643867
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
Matusali G, Vergori A, Cimini E, Mariotti D, Mazzotta V, Lepri AC, Colavita F, Gagliardini R, Notari S, Meschi S, Fusto M, Tartaglia E, Girardi E, Maggi F, Antinori A; HIV‐VAC Study Group. Matusali G, et al. Among authors: gagliardini r. J Med Virol. 2024 Apr;96(4):e29598. doi: 10.1002/jmv.29598. J Med Virol. 2024. PMID: 38624044
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study.
Lo Caputo S, Poliseno M, Tavelli A, Gagliardini R, Rusconi S, Lapadula G, Antinori A, Francisci D, Sarmati L, Gori A, Spagnuolo V, Ceccherini-Silberstein F, d'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group. Lo Caputo S, et al. Among authors: gagliardini r. Int J Infect Dis. 2024 Mar 5;143:106956. doi: 10.1016/j.ijid.2024.01.023. Online ahead of print. Int J Infect Dis. 2024. PMID: 38447754 Free article.
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. Clemente T, et al. Among authors: gagliardini r. BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort.
Gagliardini R, Giacomelli A, Bozzi G, D'Arminio Monforte A, Tavelli A, Mazzotta V, Bruzzesi E, Cervo A, Saracino A, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A; ICONA Foundation study group. Gagliardini R, et al. Travel Med Infect Dis. 2024 Mar-Apr;58:102691. doi: 10.1016/j.tmaid.2024.102691. Epub 2024 Feb 8. Travel Med Infect Dis. 2024. PMID: 38336335 Free article.
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondi A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, Agrati C, Girardi E, Vaia F, Maggi F, Antinori A; Mpox Vaccine Lazio Study Group. Mazzotta V, et al. Among authors: gagliardini r. EClinicalMedicine. 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38292040 Free PMC article.
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort.
Gagliardini R, Tavelli A, Rusconi S, Lo Caputo S, Spagnuolo V, Santoro MM, Costantini A, Vergori A, Maggiolo F, Giacomelli A, Burastero G, Madeddu G, Quiros Roldan E, d'Arminio Monforte A, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Group. Gagliardini R, et al. Int J Antimicrob Agents. 2024 Jan;63(1):107018. doi: 10.1016/j.ijantimicag.2023.107018. Epub 2023 Oct 29. Int J Antimicrob Agents. 2024. PMID: 38214244 Free article.
Pharmacokinetics of tecovirimat in subjects with Mpox.
Tempestilli M, Mondi A, D'Avolio A, Forini O, Pinnetti C, Mazzotta V, Gagliardini R, Beccacece A, De Nicolò A, Faccendini P, Cimini E, Maggi F, Girardi E, Nicastri E, Boffito M, Vaia F, Antinori A. Tempestilli M, et al. Among authors: gagliardini r. Int J Antimicrob Agents. 2024 Feb;63(2):107068. doi: 10.1016/j.ijantimicag.2023.107068. Epub 2023 Dec 22. Int J Antimicrob Agents. 2024. PMID: 38141836 Free article.
88 results